Navigation Links
t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
Date:11/25/2008

FRANKFURT, Germany, November 25 /PRNewswire/ -- t2cure, a biopharmaceutical company developing regenerative medicine therapeutics from a patient's own stem cells, today announced that it has acquired a family of patents and patent applications from Innovectis, the technology transfer arm of Frankfurt University.

The patents cover a technology that allows for the rapid characterization of the potency of bone marrow-derived cells in the treatment of cardiovascular diseases. The potency of stem cells characterizes their potential to induce or perform repair processes in adult tissue. Recent drafts and guidelines from EMEA and FDA have made clear that potency testing will be a key criterion for batch release, and thus for market approval, of stem cell-based therapies.

"This acquisition of patent rights is a significant contribution to our regulatory strategy, as our lead product is advancing into a pivotal Phase III study in acute myocardial infarction," said Manfred Ruediger, CEO t2cure. "These patent rights complement our existing IP portfolio, supporting our commitment to make stem cell-based therapeutics a clinical reality for patients suffering from an acute heart attack or chronic heart failure."

Each year, 40,000 patients are hit by a severe heart attack in Germany alone and many more are suffering from chronic heart disease. Currently there is no treatment available that can reverse the damage to diseased heart muscle. In clinical trials, stem cell-based therapies under development by t2cure have demonstrated the potential to repair damaged tissue.

t2cure will use its technology for potency testing to confirm product specifications in the course of its upcoming pivotal Phase III study in acute myocardial infarction. This study, which will enroll up to 1,400 patients, is scheduled to enroll its first patients in the second quarter of 2009.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and is now prepared to enter Phase III. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.

    Contact

    Manfred Ruediger, CEO
    t2cure GmbH
    Bettinastrasse 35-37
    D-60325 Frankfurt am Main
    Tel: +49-69-75-61-46-87-0
    Fax: +49-69-75-61-46-87-9
    Email: info@t2cure.com
   http://www.t2cure.com


'/>"/>
SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
3. Vyta Corp Acquires 100% Ownership of BIOAGRA, LLC
4. Affitech Acquires Pharmexas Diabody Technology
5. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
6. CPA Acquires Renowned German Patent Research Specialist, SVPG
7. Circassia Acquires North American and Japanese Rights to Dopexamine
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
10. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
11. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... study that validated the ability of the Aethlon HemopurifierĀ® ... increased mortality in immune-suppressed sepsis patients and also contribute ... The objective of the study was to validate the ... virus (EBV) and Herpes Simplex virus 1 (HSV1) by ...
(Date:2/22/2017)... ... 22, 2017 , ... Pharma and biotech consulting firm ... Operating from Pennsideā€™s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 years ... than a decade with leading market research firm, GfK. He began his pharma ...
(Date:2/22/2017)... RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017  United ... announced its financial results for the fourth quarter ... annual 2016 financial results reflect continued growth as ... $700 million," said Martine Rothblatt, Ph.D., United Therapeutics, ... strengthen our ability to develop and advance our ...
(Date:2/21/2017)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... months ended December 31, 2016. SQI is ... company that develops and commercializes proprietary technologies and products for ... ... milestones achieved in fiscal 2016," said Andrew Morris , ...
Breaking Biology Technology:
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/19/2017)... 19, 2017 According to a new report published by ... - 2022," the global biometric sensor market is expected to garner $1.5 billion ... 2015, Asia-Pacific dominated the global market and contributed over ... Continue Reading ... ...
Breaking Biology News(10 mins):